Transferred from: Medicilon

In the Spring Festival in 2025, "Nezha: The Demon Boy in the Sea" will have a total box office of 9.182 billion yuan, entering the top 25 of the global film history box office list. The "Nezha Spirit" highlighted in the film has already broken through the scope of myths and stories, crossed over to all walks of life in reality, and also radiated a shining light in the field of biomedicine. This firm belief resonates with Medicilon's 21-year journey in the field of preclinical research and development.

When China's biopharmaceutical industry is facing the challenges of the third phase - the involution of innovative drugs, the cold winter of capital, and the dilemma of going overseas, Medicilon takes AI+CRO as the hot wheel, technological innovation as the sky, global layout of the Qiankun circle, and quality system as the spiritual pearl, and tempers the hard core power belonging to China's research and development in the "alchemy furnace" of biomedicine.

If there is no road ahead, I will step out of the way!

If heaven and earth do not allow it, I will turn this situation around!

Hot Wheels Speed

AI+CRO, breaking the shackles of time

In the film, Nezha steps on the Hot Wheels, breaks the waves, and is omnipotent. With its unique creativity and exquisite use of modern technology, director Dumpling has given new life and visual shock to this ancient myth. In the field of drug research and development, Medicilon uses AI technology to break through the traditional cycle limitations, and technological innovation reinterprets the "China speed".

　　1

AI-enabled drug discovery

Medicilon AI drug discovery service platform is also like Hot Wheels, which can provide services such as protein structure prediction and simulation, binding site discovery, information extraction and cleaning, and customized project database construction.

　　2

One-stop biomedical preclinical service platform

The platform realizes the seamless connection from drug discovery, pharmaceutical research to preclinical research, forming an efficient and smooth R&D link, providing solid support for new drugs to quickly obtain clinical trial approval.

"Do you want to change the world?"

"I want to try."

[Innovation].

Cutting-edge technology, breaking through the boundaries of R&D

In the film, Nezha can always turn the situation around and save the day at a critical moment with the magic weapon of Chaotian Aya. It is not only a symbol of strength and wisdom, but also a symbol of Nezha's fearless courage and determination in the face of challenges. In the field of preclinical research and development, Medicilon uses cutting-edge technology as a sharp weapon to constantly break through the difficulties and obstacles in the research and development process.

　　1

New Molecule Drug Development Service Matrix

In the field of R&D of new molecular types of drugs such as ADCs, PROTACs, nucleic acid drugs, bispecific antibodies, peptides, vaccines, and cell and gene therapy (CGT), Medicilon has built a one-stop biomedical preclinical R&D service platform to empower industry innovation and development.

　　2

Continuously iterate on the one-stop service platform

In 2024 alone, Medicilon will promote drug discovery through the application of "click chemistry" and the construction of a small molecule drug synthase library. Establish a new target screening platform to overcome the problem of "undruggable"; Improve the PROTAC & molecular glue platform and ADC service platform, and deepen the antibody transformation and process optimization. At the same time, upgrade the preparation service and build a high-end preparation platform; innovative pharmacokinetic technologies, such as exosome drug bioanalysis; Challenge the problem of drug resistance and develop drug resistance models. In addition, Medicilon continues to build a variety of efficacy evaluation models to empower new drug research and meet clinical needs.

You still have to go on your way

From now on, stay true to your heart's choice!

[Qiankun Circle: Breaking the Boundary].

The global ecology empowers new drugs to go overseas

In "Nezha's Demon Boy in the Sea", the dragon clan is trapped at the bottom of the sea due to identity prejudice, but finally finds a new way out by trying to break the boundary. New drugs also face geographical, cultural, regulatory and other obstacles. In order to broaden the path of development, Medicilon has actively established a globalization strategy, including setting up R&D centers overseas and conducting collaborative research with international partners. These measures not only enhance Medicilon's international competitiveness, but also empower pharmaceutical companies to enter the international market.

　　1

Support the double report of China and the United States

As one of the first CRO companies in China to provide a complete set of new drug clinical research applications that meet both Chinese GLP and US GLP standards, Medicilon has helped 86 INDs to be approved by the FDA for clinical trials, including 5 in China, the United States and Australia, 60 in China and the United States, and 21 in the US FDA.

　　2

New drugs empower the ecosystem

Establish an academician innovative drug maturation center, build a new drug investment and financing assistance platform, a drug research and development trading platform, etc., build a new drug empowerment ecosystem, and promote the deep integration of production, learning, research and finance.

　　3

Global R&D center layout

From Zhangjiang and Chuansha in Shanghai to Nanhui and Baoshan, to Hangzhou in Zhejiang Province and Boston in the United States, Medicilon's R&D network is rapidly expanding around the world and is building a cross-border R&D ecosystem.

I've worked hard every day over the years, and I've never been lazy!

[Spirit Bead Ingenuity].

Quality first, creating a gold standard for R&D

The success of Nezha's movie is inseparable from the director and team's extreme pursuit of details. Similarly, Medicilon also pays attention to refined operation and quality management in the process of drug research and development. Through the introduction of a standardized system, optimization of the R&D process, and improvement of technical capabilities, Medicilon continues to improve its service quality to ensure that it provides customers with more efficient and reliable preclinical R&D services.

　　1

International standard system

Medicilon now has a 29,000-square-meter laboratory that has obtained the qualification of NMPA drug GLP laboratory, which meets the GLP laboratory standards of the U.S. FDA, AUSTA TGA, and EMEA. The animal experiment facility has passed AAALAC certification and can raise non-human primates, dogs, rats, rabbits, guinea pigs, miniature pigs and other types of experimental animals at the same time; And through the ABSL-2 record, with the CNAS qualification certificate of the national accredited laboratory, etc. These high-standard, international hardware facilities and qualification certifications, like Nezha's cultivation place in mythology, provide solid support and guarantee for Medicilon in the journey of new drug research and development.

　　2

Supported by a team of experts

Recently, Medicilon ushered in a new group of senior management team, including international scientific research talents and senior industry experts. Including Hu Jianglin, co-CEO & chief strategy officer of senior executives of Jiaoda Onlly (rights protection) and Fosun Pharma, Dr. Luo Jialiang, the project leader of DuPont China, Pfizer and other enterprises, and the current chief operating officer & senior vice president of pharmaceutical research, Dr. Lin Qingcong, executive vice president and president of the U.S. subsidiary of Wyeth, Pfizer and other pharmaceutical companies, and Dr. Lilly Xu, who has served as senior executives of ChemPartner and Icagen, and is now the CTO, and the owner of GSK, Dr. Maosheng Duan, Executive Vice President of Drug Discovery Business Unit at HD Biologics, and Dr. Pin Jiang, Supervisor of ChemPartner and other companies, among others. Under the leadership of Chairman Chen Chunlin, they will work hard to promote the deep integration and development of gold standard quality and innovation and development.

From the box office myth of "Nezha's Demon Boy in the Sea" to the rise of China's innovative drugs, the spiritual totem of "not accepting fate" is rewriting the industrial pattern. The "change of life" of China's biomedicine has never been to overturn the rules, but to rewrite the rules with hard-core innovation. In the future, Medicilon will continue to promote technological innovation at the speed of Hot Wheels, break through the boundaries of R&D with "Mixed Sky Aya Toughness", and work with global partners to carve the answer of this era on the "God List" of life sciences.

(The story is not over, and the struggle continues.) ）

About Medicilon

Medicilon (stock code: 688202.HK) Founded in 2004 and headquartered in Shanghai, SH is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and researchers. Medicilon's one-stop comprehensive service helps customers accelerate the process of new drug development with strong project management and more efficient and cost-effective R&D services, covering the whole process of pharmaceutical preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research. By the end of 2024, Medicilon has provided drug R&D services to more than 2,000 customers around the world, and has participated in the research and development of about 520 IND clinical trials of new drugs and generic drugs, growing together with high-quality customers at home and abroad. Medicilon will continue to be based on a global vision, focus on China's innovation, and contribute to human health!

(Redirected from: Medicilon).